Company Profile

Alzheon Inc is a United States-based clinical-stage biopharmaceutical company. The company is developing medicines for patients suffering from alzheimer's disease and other neurological and psychiatric disorders. The Company is focused on brain health, memory and aging and develops treatments for alzheimer's disease and other neurodegenerative disorders.

Employees

Sector

Biotechnology & Medical Research

More about the company

07-06	Alzheon Presents New Evidence of Neurovascular Protection and Preserved Brain Microstructure from Oral Valiltramiprosate Trials in Apoe4/4 Alzheimer?S Patients At Aaic 2026 Conference	CI
04-14	Alzheon Inc Presents Evidence of Neurovascular Protection and Clinical Outcomes for Oral Valiltramiprosate in Apoe4/4 Alzheimer?S Patients	CI
04-07	Alzheon Inc Advances Oral Anti-Amyloid Aggregation Inhibitors With First Subject Dosed In Phase 1 Of ALZ-507	CI
03-10	Alzheon Inc Presents Clinical Imaging and Fluid Biomarker Results from Trials with Oral Valiltramiprosate Alz-801	CI
02-03	Alzheon Reports Plasma Biomarker Results from Phase 3 and 2 Studies of Valiltramiprosate/ALZ-801	CI
12-02	Alzheon Announces Peer-Reviewed Publication Providing Evidence for Hippocampal Volume as Surrogate Marker for Clinical Benefit and Neurodegeneration in Early Alzheimer?S Disease	CI
11-19	Alzheon, Inc. Announces to Present Multiple Clinical, Neuroimaging and Modeling Results for Oral Valiltramiprosate/ALZ-801 from Phase 2 and 3 Studies at CTAD Conference in San Diego	CI
25-10-14	Alzheon, Inc. Announces Peer-Reviewed Scientific Publication of Results from Pivotal Apolloe4 Phase 3 Trial of Oral Valiltramiprosate/Alz-801 in Apolloe4/4 Homozygous Individuals with Early Alzheimer's Disease	CI
25-07-15	Alzheon, Inc. to Present Insights into Oral Valiltramiprosate/Alz-801 Mode of Action and Clinical Efficacy At Dedicated Symposium At Alzheimer's Association International Conference in Toronto on July 30, 2025	CI
25-04-10	Alzheon, Inc. Announces Topline Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 in Patients with Early Alzheimer's Disease Carrying Two Copies of APOLLOE4 Gene	CI
25-03-18	Alzheon, Inc. to Present Results from Pivotal Apolloe4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 At Dedicated Symposium At ADPDConference in Vienna on April 1, 2025	CI
25-02-09	Alzheon, Inc. announced that it has received $126.259938 million in funding	CI
25-01-07	Alzheon, Inc. Appoints Muneer A. Satter, Jd, Mba to Its Board	CI

Manager	Title	Age	Since
Martin Tolar CEO	Chief Executive Officer	61	2013-05-31
Kenneth A. Mace DFI	Director of Finance/CFO	54	-
Adem Albayrak COO	Chief Operating Officer	-	2021-09-12

Director	Title	Age	Since
Martin Tolar BRD	Director/Board Member	61	2013-05-31
Neil Flanzraich CHM	Chairman	83	-
Jordan Heller BRD	Director/Board Member	64	2020-01-07

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZHEON, INC.	-.--%	-.--%	-	-	0
LONZA GROUP AG	-0.11%	-2.38%	+2.06%	+19.57%	48.84B
REVOLUTION MEDICINES, INC.	+1.89%	+4.36%	+494.71%	+637.45%	45.44B
BEONE MEDICINES AG	+1.83%	+2.83%	+14.87%	+91.99%	41.22B
IQVIA HOLDINGS INC.	-0.50%	-0.81%	+25.61%	+12.05%	39.71B
CELLTRION, INC.	-2.74%	-2.74%	+17.30%	+56.10%	32.6B
ASCENDIS PHARMA A/S	+0.59%	-2.65%	-	-	16.25B
MEDPACE HOLDINGS, INC.	-1.14%	-2.01%	+28.93%	+132.78%	16.67B
EUROFINS SCIENTIFIC SE	-0.49%	-0.54%	+2.96%	+27.12%	14.08B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.60%	+0.79%	+78.19%	+39.69%	13.68B
Average	-0.33%	-0.78%	+83.08%	+127.09%	29.83B
Weighted average by Cap.	-0.02%	-0.84%	+104.53%	+155.24%

Alzheon, Inc. Stock

Stocks

ALZH

US00168L1017

Biotechnology & Medical Research

Latest news : Alzheon, Inc.

Managers and Directors: Alzheon, Inc.

Other Biotechnology & Medical Research

Company Profile